Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Loading...
Embargo End Date
ICR Authors
Authors
Mackay, A
Burford, A
Molinari, V
Jones, DTW
Izquierdo, E
Brouwer-Visser, J
Giangaspero, F
Haberler, C
Pietsch, T
Jacques, TS
Figarella-Branger, D
Rodriguez, D
Morgan, PS
Raman, P
Waanders, AJ
Resnick, AC
Massimino, M
Garrè, ML
Smith, H
Capper, D
Pfister, SM
Würdinger, T
Tam, R
Garcia, J
Thakur, MD
Vassal, G
Grill, J
Jaspan, T
Varlet, P
Jones, C
Burford, A
Molinari, V
Jones, DTW
Izquierdo, E
Brouwer-Visser, J
Giangaspero, F
Haberler, C
Pietsch, T
Jacques, TS
Figarella-Branger, D
Rodriguez, D
Morgan, PS
Raman, P
Waanders, AJ
Resnick, AC
Massimino, M
Garrè, ML
Smith, H
Capper, D
Pfister, SM
Würdinger, T
Tam, R
Garcia, J
Thakur, MD
Vassal, G
Grill, J
Jaspan, T
Varlet, P
Jones, C
Document Type
Journal Article
Date
2018-05-14
Date Accepted
2018-04-10
Abstract
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term "HGG" in the pediatric population.
Citation
Cancer cell, 2018, 33 (5), pp. 829 - 842.e5
Source Title
Publisher
CELL PRESS
ISSN
1535-6108
eISSN
1878-3686
Collections
Research Team
Glioma Team